þ
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF
1934
|
¨
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF
1934
|
Minnesota
(State
or other jurisdiction of incorporation or
organization)
|
41-1458152
(I.R.S.
Employer
Identification
No.)
|
350
Hills St., Suite 106, Richland, Washington
(Address
of principal executive offices)
|
99354
(Zip
Code)
|
Class
|
Outstanding as of February 8, 2011
|
|
Common
stock, $0.001 par value
|
25,816,476
|
PART
I
|
FINANCIAL
INFORMATION
|
|
Item
1
|
Consolidated
Unaudited Financial Statements
|
1
|
Consolidated
Balance Sheets (Unaudited)
|
1
|
|
Consolidated
Statements of Operations (Unaudited)
|
2
|
|
Consolidated
Statements of Cash Flows (Unaudited)
|
3
|
|
Notes
to Unaudited Consolidated Financial Statements
|
4
|
|
Item
2
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
10
|
Item
3
|
Quantitative
and Qualitative Disclosures About Market Risk
|
23
|
Item
4
|
Controls
and Procedures
|
23
|
PART
II
|
OTHER
INFORMATION
|
|
Item
1A
|
Risk
Factors
|
23
|
Item
2
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
27
|
Item
6
|
Exhibits
|
30
|
Signatures
|
31
|
(Unaudited)
|
||||||||
December 31,
|
June 30,
|
|||||||
2010
|
2010
|
|||||||
ASSETS
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ | 2,770,366 | $ | 1,678,869 | ||||
Accounts
receivable, net of allowance for doubtful accounts
|
||||||||
of
$32,153 and $36,390, respectively
|
1,008,779 | 896,266 | ||||||
Inventory
|
775,167 | 681,677 | ||||||
Prepaid
expenses and other current assets
|
245,613 | 259,975 | ||||||
Total
current assets
|
4,799,925 | 3,516,787 | ||||||
Fixed
assets, net of accumulated depreciation and amortization
|
3,546,219 | 3,959,983 | ||||||
Deferred
financing costs, net of accumulated amortization
|
156,144 | 13,277 | ||||||
Restricted
cash
|
180,556 | 180,154 | ||||||
Other
assets, net of accumulated amortization
|
275,206 | 272,594 | ||||||
Total
assets
|
$ | 8,958,050 | $ | 7,942,795 | ||||
LIABILITIES
AND SHAREHOLDERS' EQUITY
|
||||||||
Current
liabilities:
|
||||||||
Accounts
payable and accrued liabilities
|
$ | 454,715 | $ | 404,401 | ||||
Accrued
protocol expense
|
69,528 | 242,029 | ||||||
Accrued
radioactive waste disposal
|
84,060 | 60,060 | ||||||
Accrued
payroll and related taxes
|
135,675 | 186,513 | ||||||
Acccued
vacation
|
71,172 | 68,525 | ||||||
Notes
payable, due within one year
|
52,985 | 49,445 | ||||||
Total
current liabilities
|
868,135 | 1,010,973 | ||||||
Notes
payable, due after one year
|
101,677 | 130,550 | ||||||
Warrant
liabilities
|
1,304,000 | - | ||||||
Asset
retirement obligation
|
633,149 | 605,391 | ||||||
Total
liabilities
|
2,906,961 | 1,746,914 | ||||||
Commitments
and contingencies (Note 6)
|
||||||||
Shareholders'
equity:
|
||||||||
Preferred
stock, $.001 par value; 6,000,000 shares authorized:
|
||||||||
Series
A: 1,000,000 shares allocated; no shares issued and
outstanding
|
- | - | ||||||
Series
B: 5,000,000 shares allocated; 59,065 shares issued and
outstanding
|
59 | 59 | ||||||
Common
stock, $.001 par value; 194,000,000 shares authorized;
|
||||||||
25,829,325
and 23,048,754 shares issued and outstanding
|
25,829 | 23,049 | ||||||
Treasury
stock, at cost, 13,200 shares
|
(8,390 | ) | (8,390 | ) | ||||
Additional
paid-in capital
|
49,037,162 | 48,084,783 | ||||||
Accumulated
deficit
|
(43,003,571 | ) | (41,903,620 | ) | ||||
Total
shareholders' equity
|
6,051,089 | 6,195,881 | ||||||
Total
liabilities and shareholders' equity
|
$ | 8,958,050 | $ | 7,942,795 |
Three months ended December 31,
|
Six months ended December 31,
|
|||||||||||||||
2010
|
2009
|
2010
|
2009
|
|||||||||||||
Product
sales
|
$ | 1,244,922 | $ | 1,368,347 | $ | 2,572,049 | $ | 2,747,434 | ||||||||
Cost
of product sales
|
1,117,005 | 1,100,193 | 2,228,532 | 2,260,282 | ||||||||||||
Gross
income
|
127,917 | 268,154 | 343,517 | 487,152 | ||||||||||||
Operating
expenses:
|
||||||||||||||||
Research
and development expenses
|
15,612 | 59,078 | 130,133 | 127,960 | ||||||||||||
Sales
and marketing expenses
|
335,612 | 603,980 | 709,038 | 1,046,879 | ||||||||||||
General
and administrative expenses
|
561,208 | 550,009 | 1,157,341 | 1,152,440 | ||||||||||||
Total
operating expenses
|
912,432 | 1,213,067 | 1,996,512 | 2,327,279 | ||||||||||||
Operating
loss
|
(784,515 | ) | (944,913 | ) | (1,652,995 | ) | (1,840,127 | ) | ||||||||
Non-operating
income (expense):
|
||||||||||||||||
Interest
income
|
979 | 2,944 | 2,040 | 8,811 | ||||||||||||
Gain
on fair value of warrant liability
|
420,000 | - | 420,000 | - | ||||||||||||
Other
income
|
149,879 | 149,879 | ||||||||||||||
Financing
and interest expense
|
(14,412 | ) | (7,898 | ) | (18,875 | ) | (25,259 | ) | ||||||||
Non-operating
income (expense), net
|
556,446 | (4,954 | ) | 553,044 | (16,448 | ) | ||||||||||
Net
loss
|
(228,069 | ) | (949,867 | ) | (1,099,951 | ) | (1,856,575 | ) | ||||||||
Preferred
stock dividends
|
(2,658 | ) | (36,679 | ) | (5,316 | ) | (36,679 | ) | ||||||||
Net
loss applicable to common shareholders
|
$ | (230,727 | ) | $ | (986,546 | ) | $ | (1,105,267 | ) | $ | (1,893,254 | ) | ||||
Basic
and diluted loss per share
|
$ | (0.01 | ) | $ | (0.04 | ) | $ | (0.05 | ) | $ | (0.08 | ) | ||||
Weighted
average shares used in computing net loss per share:
|
||||||||||||||||
Basic
and diluted
|
25,070,992 | 22,942,088 | 24,059,873 | 22,942,088 |
Six months ended December 31,
|
||||||||
2010
|
2009
|
|||||||
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
Net
loss
|
$ | (1,099,951 | ) | $ | (1,856,575 | ) | ||
Adjustments
to reconcile net loss to net cash used by operating
activities:
|
||||||||
Depreciation
and amortization of fixed assets
|
446,740 | 484,572 | ||||||
Amortization
of deferred financing costs and other assets
|
26,702 | 29,100 | ||||||
Gain
on fair value of warrant liabilities
|
(420,000 | ) | - | |||||
Accretion
of asset retirement obligation
|
27,758 | 25,378 | ||||||
Share-based
compensation
|
48,250 | 80,477 | ||||||
Changes
in operating assets and liabilities:
|
||||||||
Accounts
receivable, net
|
(112,513 | ) | (174,867 | ) | ||||
Inventory
|
(93,490 | ) | 35,361 | |||||
Prepaid
expenses and other current assets
|
35,232 | (3,972 | ) | |||||
Accounts
payable and accrued expenses
|
50,314 | 18,817 | ||||||
Accrued
protocol expense
|
(172,501 | ) | 11,878 | |||||
Accrued
radioactive waste disposal
|
24,000 | (23,940 | ) | |||||
Accrued
payroll and related taxes
|
(50,838 | ) | 16,552 | |||||
Accrued
vacation
|
2,647 | (17,702 | ) | |||||
Net
cash used by operating activities
|
(1,287,650 | ) | (1,374,921 | ) | ||||
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
Purchases
of fixed assets
|
(32,976 | ) | (18,000 | ) | ||||
Change
in restricted cash
|
(402 | ) | (1,049 | ) | ||||
Proceeds
from the sale or maturity of short-term investments
|
- | 1,679,820 | ||||||
Net
cash provided (used) by investing activities
|
(33,378 | ) | 1,660,771 | |||||
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
Principal
payments on notes payable
|
(25,333 | ) | (134,331 | ) | ||||
Preferred
dividends paid
|
(10,632 | ) | (36,679 | ) | ||||
Proceeds
from sales of common stock and warrants, net of offering
costs
|
||||||||
pursuant
to registered public offering
|
1,998,040 | - | ||||||
Proceeds
from sales of common stock, net of offering costs
|
||||||||
pursuant
to at the market offering
|
250,632 | - | ||||||
Proceeds
from sales of common stock, pursuant to exercise of
warrants
|
199,818 | - | ||||||
Net
cash used by financing activities
|
2,412,525 | (171,010 | ) | |||||
Net
increase (decrease) in cash and cash equivalents
|
1,091,497 | 114,840 | ||||||
Cash
and cash equivalents, beginning of period
|
1,678,869 | 2,990,744 | ||||||
CASH
AND CASH EQUIVALENTS, END OF PERIOD
|
$ | 2,770,366 | $ | 3,105,584 | ||||
Supplemental
disclosures of cash flow information:
|
||||||||
Non-cash
investing and financing activities:
|
||||||||
Initial
measurement of warrant liabilities
|
$ | 1,724,000 | $ | - |
1.
|
Basis
of Presentation
|
December
31,
|
||||||||
2010
|
2009
|
|||||||
Preferred
stock
|
59,065 | 59,065 | ||||||
Common
stock warrants
|
5,173,945 | 3,216,644 | ||||||
Common
stock options
|
2,146,372 | 2,412,236 | ||||||
Total
potential dilutive securities
|
7,379,382 | 5,687,945 |
December 31,
|
June 30,
|
|||||||
2010
|
2010
|
|||||||
Raw
materials
|
$ | 654,580 | $ | 546,080 | ||||
Work
in process
|
103,323 | 130,840 | ||||||
Finished
goods
|
17,264 | 4,757 | ||||||
$ | 775,167 | $ | 681,677 |
Three months
|
Six months
|
|||||||||||||||
ended December 31,
|
ended December 31,
|
|||||||||||||||
2010
|
2009
|
2010
|
2009
|
|||||||||||||
Cost
of product sales
|
$ | 8,470 | $ | 5,375 | $ | 16,940 | $ | 11,272 | ||||||||
Research
and development expenses
|
5,410 | 174 | 10,820 | 336 | ||||||||||||
Sales
and marketing expenses
|
3,847 | 27,460 | 7,694 | 51,085 | ||||||||||||
General
and administrative expenses
|
5,930 | (10,459 | ) | 12,795 | 17,784 | |||||||||||
Total
share-based compensation
|
$ | 23,657 | $ | 22,550 | $ | 48,249 | $ | 80,477 |
Weighted
|
||||||||||||||||
Weighted
|
Average
|
|||||||||||||||
Average
|
Remaining
|
Aggregate
|
||||||||||||||
Number
of
|
Exercise
|
Contractual
|
Intrinsic
|
|||||||||||||
Options
|
Price
|
Term
|
Value
|
|||||||||||||
Outstanding
at December 31, 2010
|
2,146,372 | $ | 1.87 | 6.8 | $ | 645,522 | ||||||||||
Vested
and expected to vest at December 31, 2010
|
2,059,546 | $ | 1.93 | 6.7 | $ | 587,179 | ||||||||||
Vested
and exercisable at December 31, 2010
|
1,614,293 | $ | 2.27 | 6.3 | $ | 355,198 |
Three months
|
Six months
|
|||||||||||||||
ended December 31,
|
ended December 31,
|
|||||||||||||||
2010(a)
|
2009(b)
|
2010(c)
|
2009(d)
|
|||||||||||||
Weighted
average fair value of options granted
|
$ | - | $ | - | $ | - | $ | 0.51 | ||||||||
Key
assumptions used in determining fair value:
|
||||||||||||||||
Weighted
average risk-free interest rate
|
- | % | - | % | - | % | 2.50 | % | ||||||||
Weighted
average life of the option (in years)
|
- | - | - | 4.00 | ||||||||||||
Weighted
average historical stock price volatility
|
- | % | - | % | - | % | 132.21 | % | ||||||||
Expected
dividend yield
|
- | % | - | % | - | % | 0.00 | % |
(a)
|
During
the three months ended December 31, 2010, the Company did not grant any
stock options.
|
(b)
|
During
the three months ended December 31, 2009, the Company did not grant any
stock options.
|
(c)
|
During
the six months ended December 31, 2010, the Company did not grant any
stock options.
|
(d)
|
During
the six months ended December 31, 2009, the Company granted 10,000 stock
options.
|
Weighted average
|
||||||||
Warrants
|
exercise price
|
|||||||
Outstanding
as of June 30, 2010
|
3,165,768 | $ | 5.550 | |||||
Series
A warrants
|
508,130 | $ | 0.984 | |||||
Series
B warrants
|
562,500 | $ | 0.984 | |||||
Series
C warrants
|
1,096,391 | $ | 0.984 | |||||
Warrants
exercised
|
(226,344 | ) | $ | 0.950 | ||||
Outstanding
as of December 31, 2010
|
5,173,945 | $ | 3.610 |
Series
A deferred costs
|
$ | 21,391 |
4
months
|
$ | 5,348 per month | ||||
Series
B deferred costs
|
$ | 26,431 |
6
months
|
$ | 4,405 per month | ||||
Series
C deferred costs
|
$ | 145,230 |
60
months
|
$ | 2,420 per month |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Product
Sales (Prostate)
|
$ | 1,139,530 | $ | 1,323,047 | $ | (183,517 | ) | (14 | )% | |||||||
Product
Sales (Other)
|
$ | 105,392 | $ | 45,300 | $ | 60,092 | 133 | % | ||||||||
Total
product sales
|
$ | 1,244,922 | $ | 1,368,347 | $ | (123,425 | ) | (9 | )% |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Material
|
$ | 430,777 | $ | 394,537 | $ | 36,240 | 9 | % | ||||||||
Pre-loading
|
$ | 97,153 | $ | 85,967 | $ | 11,186 | 13 | % | ||||||||
Payroll
and benefits
|
$ | 204,629 | $ | 235,533 | $ | (30,904 | ) | (13 | )% | |||||||
Cost of product sales
(Other)
|
$ | 384,447 | $ | 384,156 | $ | 290 | 0 | % | ||||||||
Total
cost of product sales
|
$ | 1,117,005 | $ | 1,100,193 | $ | 16,812 | 2 | % |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Gross
margin
|
$ | 127,917 | $ | 268,154 | $ | (140,237 | ) | (52 | )% | |||||||
Gross margin percentage
|
10 | % | 20 | % |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Other
organ research
|
$ | 23,525 | $ | 20 | $ | 23,505 | 117,525 | % | ||||||||
Payroll
and benefits
|
$ | 78,471 | $ | 3,316 | $ | 75,155 | 2,266 | % | ||||||||
Protocol
expense
|
$ | (134,031 | ) | $ | 22,500 | $ | (156,531 | ) | (696 | )% | ||||||
Travel
expense
|
$ | 12,260 | $ | - | $ | 12,260 | 100 | % | ||||||||
Research
and development (Other)
|
$ | 35,387 | $ | 33,242 | $ | 2,145 | 6 | % | ||||||||
Total
research and development
|
$ | 15,612 | $ | 59,078 | $ | (43,466 | ) | (74 | )% |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Consulting
|
$ | 220 | $ | 23,749 | $ | (23,529 | ) | (99 | )% | |||||||
Conventions
and tradeshows
|
$ | 12,381 | $ | 78,131 | $ | (65,750 | ) | (84 | )% | |||||||
Marketing
and advertising
|
$ | 22,432 | $ | 62,676 | $ | (40,244 | ) | (64 | )% | |||||||
Payroll,
benefits & share comp
|
$ | 231,623 | $ | 322,452 | $ | (90,829 | ) | (28 | )% | |||||||
Travel
|
$ | 52,526 | $ | 74,833 | $ | (22,307 | ) | (30 | )% | |||||||
Sales and marketing (Other)
|
$ | 16,430 | $ | 42,139 | $ | (25,709 | ) | (61 | )% | |||||||
Total
sales and marketing
|
$ | 335,612 | $ | 603,980 | $ | (268,368 | ) | (44 | )% |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Audit,
SOX and tax
|
$ | 5,710 | $ | 23,456 | $ | (17,746 | ) | (76 | )% | |||||||
Consulting
|
$ | 85,954 | $ | 72,031 | $ | 13,923 | 19 | % | ||||||||
Legal
|
$ | 43,387 | $ | 69,902 | $ | (26,515 | ) | (38 | )% | |||||||
Payroll,
benefits & share comp
|
$ | 242,866 | $ | 204,123 | $ | 38,743 | 19 | % | ||||||||
Public
company
|
$ | 82,785 | $ | 69,282 | $ | 13,503 | 19 | % | ||||||||
General and administrative
(Other)
|
$ | 100,506 | $ | 111,215 | $ | (10,709 | ) | (10 | )% | |||||||
Total
general and administrative
|
$ | 561,208 | $ | 550,009 | $ | 11,199 | 2 | % |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Operating
loss
|
$ | (784,515 | ) | $ | (944,913 | ) | $ | 160,398 | 17 | % |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Interest
income
|
$ | 979 | $ | 2,944 | $ | (1,965 | ) | (67 | )% |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Gain
on fair value of warrant liability
|
$ | 420,000 | $ | - | $ | 420,000 | 100 | % |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Other
grant income (FY 2010)
|
$ | 109,316 | $ | - | $ | 109,316 | 100 | % | ||||||||
Other
grant income (FY2011)
|
$ | 40,513 | $ | - | $ | 40,513 | 100 | % | ||||||||
Other income
|
$ | 50 | $ | - | $ | 50 | 100 | % | ||||||||
Total
other income
|
$ | 149,879 | $ | - | $ | 149,879 | 100 | % |
Three months
|
Three months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Interest
expense
|
$ | 1,685 | $ | 4,171 | $ | (2,486 | ) | (60 | )% | |||||||
Deferred financing expense
|
$ | 12,727 | $ | 3,727 | $ | 9,000 | 241 | % | ||||||||
Total
financing and interest expense
|
$ | 14,412 | $ | 7,898 | $ | 6,514 | 82 | % |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Product
Sales (Prostate)
|
$ | 2,372,657 | $ | 2,670,134 | $ | (297,477 | ) | (11 | )% | |||||||
Product Sales (Other)
|
$ | 199,392 | $ | 77,300 | $ | 122,092 | 158 | % | ||||||||
Total
product sales
|
$ | 2,572,049 | $ | 2,747,434 | $ | (175,385 | ) | (6 | )% |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Depreciation
and amortization
|
$ | 444,075 | $ | 467,081 | $ | (23,006 | ) | (5 | )% | |||||||
Material
|
$ | 859,353 | $ | 816,510 | $ | 42,843 | 5 | % | ||||||||
Occupancy
|
$ | 148,006 | $ | 129,567 | $ | 18,439 | 14 | % | ||||||||
Payroll
and benefits
|
$ | 411,662 | $ | 483,185 | $ | (71,523 | ) | (15 | )% | |||||||
Cost of product sales
(Other)
|
$ | 365,436 | $ | 363,939 | $ | 1,497 | 0 | % | ||||||||
Total
cost of product sales
|
$ | 2,228,532 | $ | 2,260,282 | $ | (31,750 | ) | (1 | )% |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Gross
margin
|
$ | 343,517 | $ | 487,152 | $ | (143,635 | ) | (29 | )% | |||||||
Gross margin percentage
|
13 | % | 18 | % |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Other
organ research
|
$ | 25,850 | $ | 3,171 | $ | 22,679 | 715 | % | ||||||||
Payroll
and benefits
|
$ | 138,414 | $ | 5,134 | $ | 133,280 | 2,596 | % | ||||||||
Protocol
expense
|
$ | (123,063 | ) | $ | 46,700 | $ | (24,762 | ) | (364 | )% | ||||||
Travel
expense
|
$ | 24,637 | $ | 13 | $ | 24,624 | 189,415 | % | ||||||||
Research and
development (Other)
|
$ | 64,295 | $ | 72,942 | $ | (8,647 | ) | (12 | )% | |||||||
Total
research and development
|
$ | 130,133 | $ | 127,960 | $ | 2,173 | 2 | % |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Consulting
|
$ | 16,720 | $ | 39,649 | $ | (22,929 | ) | (58 | )% | |||||||
Conventions
and tradeshow
|
$ | 18,714 | $ | 103,002 | $ | (84,288 | ) | (82 | )% | |||||||
Marketing
and advertising
|
$ | 36,749 | $ | 107,734 | $ | (70,985 | ) | (66 | )% | |||||||
Payroll,
benefits & share comp
|
$ | 492,288 | $ | 582,682 | $ | (90,394 | ) | (16 | )% | |||||||
Travel
|
$ | 114,955 | $ | 132,783 | $ | (17,828 | ) | (13 | )% | |||||||
Sales
and marketing (Other)
|
$ | 29,612 | $ | 81,029 | $ | (51,417 | ) | (63 | )% | |||||||
Total
sales and marketing
|
$ | 709,038 | $ | 1,046,879 | $ | (337,841 | ) | (32 | )% |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Audit,
SOX and tax
|
$ | 58,582 | $ | 63,463 | $ | (4,881 | ) | (8 | )% | |||||||
Consulting
|
$ | 159,183 | $ | 147,529 | $ | 11,654 | 8 | % | ||||||||
Legal
|
$ | 78,316 | $ | 123,298 | $ | (44,982 | ) | (36 | )% | |||||||
Payroll,
benefits & share comp
|
$ | 487,526 | $ | 461,897 | $ | 25,629 | 6 | % | ||||||||
Public
company
|
$ | 134,128 | $ | 117,779 | $ | 16,349 | 14 | % | ||||||||
General and
administrative (Other)
|
$ | 239,606 | $ | 238,474 | $ | 6,120 | 0 | % | ||||||||
Total
general and administrative
|
$ | 1,157,341 | $ | 1,152,440 | $ | 4,901 | 0 | % |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Operating
loss
|
$ | (1,652,995 | ) | $ | (1,840,127 | ) | $ | 187,132 | (10 | )% |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Interest
income
|
$ | 2,040 | $ | 8,811 | $ | (6,771 | ) | (77 | )% |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Gain
on fair value of warrant liability
|
$ | 420,000 | $ | - | $ | 420,000 | 100 | % |
Six
months
|
Six
months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Other
grant income (FY 2010)
|
$ | 109,316 | $ | - | $ | 109,316 | 100 | % | ||||||||
Other
grant income (FY2011)
|
$ | 40,513 | $ | - | $ | 40,513 | 100 | % | ||||||||
Other income
|
$ | 50 | $ | - | $ | 50 | 100 | % | ||||||||
Total
other income
|
$ | 149,879 | $ | - | $ | 149,879 | 100 | % |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Interest
expense
|
$ | 5,596 | $ | 11,457 | $ | (5,861 | ) | (51 | )% | |||||||
Deferred financing expense
|
$ | 13,279 | $ | 13,802 | $ | (523 | ) | (4 | )% | |||||||
Total
financing and interest expense
|
$ | 18,875 | $ | 25,259 | $ | (6,384 | ) | (25 | )% |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Net
loss
|
$ | (1,099,951 | ) | $ | (1,856,575 | ) | $ | 756,624 | (41 | )% | ||||||
Non-cash
items
|
$ | 129,450 | $ | 619,527 | $ | (490,077 | ) | (79 | )% | |||||||
Non-cash changes in operating assets and
liabilities
|
$ | (317,149 | ) | $ | (137,873 | ) | $ | (179,276 | ) | 130 | % | |||||
Net
cash used by operating activities
|
$ | (1,287,650 | ) | $ | (1,374,921 | ) | $ | 87,271 | (6 | )% |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Purchases
of fixed assets
|
$ | (32,976 | ) | $ | (18,000 | ) | $ | (14,976 | ) | 83 | % | |||||
Change
in restricted cash
|
$ | (402 | ) | $ | (1,049 | ) | $ | 647 | (62 | )% | ||||||
Proceeds
from the sale or maturity of short-term investments
|
$ | - | $ | 1,679,820 | $ | 1,678,820 | 100 | % | ||||||||
Net
cash provided (used) by investing activities
|
$ | (33,378 | ) | $ | 1,660,771 | $ | (1,694,149 | ) | (102 | )% |
Six months
|
Six months
|
|||||||||||||||
Description
|
ended 12-31-10
|
ended 12-31-09
|
Variance ($)
|
Variance (%)
|
||||||||||||
Principal
payments on notes payable
|
||||||||||||||||
HAEIFC
|
$ | (25,333 | ) | $ | (18,433 | ) | $ | 6,900 | 37 | % | ||||||
BFEDD
|
$ | - | $ | (115,898 | ) | $ | (115,898 | ) | (100 | )% | ||||||
Preferred
dividend payments
|
$ | (10,632 | ) | $ | (36,679 | ) | $ | 26,047 | (71 | )% | ||||||
Proceeds
from sale of common stock
|
$ | 2,448,490 | $ | - | $ | 2,448,490 | 100 | % | ||||||||
Net
cash provided (used) by
|
||||||||||||||||
financing
activities
|
$ | 2,412,525 | $ | (171,010 | ) | $ | 2,583,535 | (1,511 | )% |
|
·
|
The
Company continues to assess opportunities to further segregate duties
within a limited staff.
|
|
·
|
The
staff is utilizing continuing professional education opportunities to
enhance their knowledge.
|
|
·
|
Management
is conducting ongoing reviews of all significant and non-routine
transactions.
|
|
31.1
|
Rule
13a-14(a)/15d-14(a) Certification of Principal Executive
Officer
|
|
31.2
|
Rule
13a-14(a)/15d-14(a) Certification of Principal Financial
Officer
|
|
32
|
Section
1350 Certifications
|
Dated:
February 14, 2011
|
||
ISORAY,
INC., a Minnesota corporation
|
||
By
|
/s/ Dwight
Babcock
|
|
Dwight
Babcock, Chief Executive Officer
(Principal
Executive Officer)
|
By
|
/s/ Brien
Ragle
|
|
Brien
Ragle, Controller
(Principal
Financial and Accounting
Officer)
|